Market Intelligence, Clinical Progress, and High-Purity Reagents for Immunotherapy and Tumor Microenvironment Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for LAIR1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | LAIR1 ECD-Fc Recombinant Protein High purity (>95%), Endotoxin <1.0 EU/μg. Sequence Verified. HEK293 expressed for native glycosylation. |
View LAIR1 Products |
| Gene Delivery | LAIR1 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and cell-based functional assays. |
View LAIR1 Products |
| Benchmark Ab | Anti-LAIR1 Recombinant Antibody (NC318 Sequence) Recombinant positive control for binding and blocking validation. |
View LAIR1 Products |
| Validator | LAIR1 siRNA Set For knockdown verification in target-specific assays. |
View LAIR1 Products |
| Related Target A | LAIR2 Soluble homolog and natural decoy receptor; essential for selectivity and counter-screening assays. |
View LAIR2 Products |
| Related Target B | LILRB4 Co-inhibitory myeloid checkpoint; evaluated for synergistic immunosuppression in the tumor microenvironment. |
View LAIR2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity over soluble decoy LAIR2 | Sequence-verified human LAIR1 and LAIR2 proteins available for high-throughput cross-reactivity screening. |
| Functional blocking of collagen binding | HEK293 expressed, natively folded LAIR1 extracellular domain (ECD) ensuring correct conformational epitopes for ligand-binding competition. |
| Lack of Controls | Clinical Benchmark Antibodies (NC318 biosimilar) included for assay calibration. |
| False Positives | Validated siRNA sets included for target-specific knockdown verification in cell-based assays. |
Live LAIR1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for LAIR1 therapeutics is intensifying, with major players shifting focus from traditional systemic immune checkpoints to targeting the collagen-mediated extracellular matrix (ECM) immunosuppressive barrier. As first-generation therapies reach the clinic, the next wave of R&D is targeting myeloid-derived suppressor cells (MDSCs) and collagen-rich "cold" tumors where standard PD-1/PD-L1 blockades fail.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | NextCure (NC318), NGM Bio (NGM438) | Solid Tumors (NSCLC, Ovarian, Colorectal) | Collagen blocking assays (Need high-purity, natively folded ECD-Fc proteins) |
| Bispecific Antibody | Biotech pipelines | Immunotherapy refractory tumors | Dual-targeting validation (Need cross-reactive antigens and stable cell lines) |
| Small Molecule / Peptide | Academic discovery | Fibrotic cancers, Autoimmune diseases | Selectivity assays (Need LAIR1 vs LAIR2 mutant recombinant protein panels) |